1	ORIGINAL ARTICLE					
2	Diagnostic performance of the combined					
3	nasal and throat swab in patients admitted					
4	to hospital with suspected COVID-19					
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 22 23	Kuan Ken I Anda Bularga, M Ingolfur Sara An Megl <sup>1</sup> BHF Centre for Cardiov <sup>2</sup> Usher Institute, Univers <sup>3</sup> Regional Infectious Dis <sup>4</sup> Department of Clinical <sup>5</sup> Department of Clinical <sup>6</sup> Department of Non-cor London, UK <sup>7</sup> Department of Cardiolo	Lee, M.D., <sup>1</sup> Dimitrios Doudesis, M.Sc., <sup>1, 2</sup> Daniella A. Ross, M.D., <sup>3</sup> M.D., <sup>1</sup> Claire L. MacKintosh, M.D., Ph.D., <sup>3</sup> Oliver Koch, M.D., Ph.D., <sup>3</sup> Johannessen, M.D., Ph.D., <sup>4</sup> Kate Templeton, Ph.D., FRCPath., <sup>4</sup> Jenks, M.D., FRCPath., <sup>5</sup> Andrew R. Chapman, M.D., Ph.D., <sup>1</sup> oop S.V. Shah, M.D., Ph.D., <sup>16,7</sup> Atul Anand, M.D., Ph.D., <sup>1</sup> an R. Perry, M.D., Ph.D., <sup>3</sup> Nicholas L. Mills, M.D., Ph.D., <sup>1,2</sup> <i>on behalf of the DataLoch COVID-19 Collaboration</i> *				
23 24 25	* Listed at the end of the	manuscript				
26 27 28 29 30 31 32 33 34	<b>Corresponding Autho</b> Professor Nicholas L M BHF/University Centre The University of Edinl Edinburgh EH16 4SA United Kingdom Telephone: 0044 131 24 E-mail: <u>nick.mills@ed.</u>	r: for Cardiovascular Science burgh 42 6515 <u>ac.uk</u>				
35 36	Abstract:	297				
37	Word count:	3,500				
38	Tables and figures:	5				
39	<b>References:</b>	23				

# 1 Abstract

Background: Accurate diagnosis in patients with suspected coronavirus disease 2019 (COVID19) is essential to guide treatment and limit spread of the virus. The combined nasal and throat
swab is used widely, but its diagnostic performance is uncertain.

5 Methods: In a prospective, multi-centre, cohort study conducted in secondary and tertiary care 6 hospitals in Scotland, we evaluated the combined nasal and throat swab with reverse 7 transcriptase-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome 8 coronavirus-2 (SARS-CoV-2) in consecutive patients admitted to hospital with suspected 9 COVID-19. Diagnostic performance of the index and serial tests was evaluated for a primary 10 outcome of confirmed or probable COVID-19, and a secondary outcome of confirmed COVID-11 19 on serial testing. The diagnosis was adjudicated by a panel, who recorded clinical, laboratory 12 and radiological features blinded to the test results.

13 Results: We enrolled 1,369 consecutive patients (68 [53-80] years, 47% women) who underwent 14 a total of 3,822 tests (median 2 [1-3] tests per patient). The primary outcome occurred in 36% 15 (496/1,369), of whom 65% (323/496) and 35% (173/496) had confirmed and probable COVID-16 19, respectively. The index test was positive in 255/496 (51%) patients with the primary 17 outcome, giving a sensitivity and specificity of 51.4% (95% confidence interval [CI] 48.8 to 18 54.1%) and 99.5% (95% CI 99.0 to 99.8%). Sensitivity increased in those undergoing 2, 3 or 4 19 tests to 60.1% (95% CI 56.7 to 63.4%), 68.3% (95% CI 64.0 to 72.3%) and 77.6% (95% CI 72.7 20 to 81.9%), respectively. The sensitivity of the index test was 78.9% (95% CI 74.4 to 83.2%) for 21 the secondary outcome of confirmed COVID-19 on serial testing.

- 1 Conclusions: In patients admitted to hospital, a single combined nasal and throat swab with RT-
- 2 PCR for SARS-CoV-2 has excellent specificity, but limited diagnostic sensitivity for COVID-19.
- 3 Diagnostic performance is significantly improved by repeated testing.
- 4 **Funding:** The British Heart Foundation
- 5

# 1 Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel strain of coronavirus,
which is responsible for the global pandemic of coronavirus disease 2019 (COVID-19).<sup>1,2</sup>
Timely and accurate diagnostic testing in patients with suspected COVID-19 is essential to guide
treatment and implement infection control measures to limit spread of the virus.

6

7 Reverse transcriptase-polymerase chain reaction (RT-PCR) assays on material collected by 8 swabbing the nose and throat are the most commonly used diagnostic tests.<sup>3</sup> However, a number 9 of reports have indicated discordance between the results of testing and clinical or radiological 10 findings in patients with symptoms of suspected COVID-19 and increasingly clusters of asymptomatic carriers of SARS-CoV-2 are recognised.<sup>4-8</sup> As such, uncertainty remains as to the 11 12 diagnostic performance of the combined nasal and throat swab to diagnose the clinical condition 13 of COVID-19, particularly in patients presenting late following the onset of symptoms when the 14 viral load may be lower.

15

16 Our aim was to evaluate the performance of the combined nasal and throat swab for the clinical

17 diagnosis of COVID-19 in consecutive patients admitted to hospital with suggestive symptoms,

18 and to determine whether there is heterogeneity across subgroups.

## 1 Methods

#### 2 Study design

3 In a prospective, multi-centre, cohort study in secondary and tertiary care hospitals in Scotland, 4 United Kingdom, we evaluated the diagnostic performance of the combined nasal and throat 5 swab with RT-PCR for SARS-CoV-2 in consecutive patients admitted to hospital for symptoms 6 of suspected COVID-19. The study was performed with approval of the local Research Ethics 7 Committee and delegated Caldicott Guardian for the National Health Service (NHS) Lothian 8 Health Board, in accordance with the Declaration of Helsinki. All data were collected from the patient record and national registries, deidentified and linked in a data repository (DataLoch<sup>TM</sup>, 9 10 Edinburgh, United Kingdom) within a secure safe haven. Individual patient consent was not 11 sought, and only summary data was extracted to minimise the risk of disclosure.

12

#### 13 **Participants**

14 Consecutive adult patients  $\geq 18$  years old were identified by the attending clinician using an 15 electronic form integrated into the care pathway at the time of testing with the combined nasal 16 and throat swab. Patients were eligible for inclusion if they were admitted to hospital with 17 symptoms suggestive of COVID-19 and had a reportable SARS-CoV-2 RT-PCR result from 18 material obtained through the combined swab (*Figure 1*). Patients were excluded if they had no 19 symptoms and testing was performed for screening purposes only, or if they had a previous 20 diagnosis of COVID-19.

21

#### 22 **Procedures**

1 During the study period RT-PCR for SARS-CoV-2 was performed on material obtained from a 2 combined nasal and throat swab in patients presenting with symptoms suggestive of COVID-19 3 who were admitted to hospital. Repeat testing was at the discretion of the clinician responsible 4 for care. RNA gene targets differ by manufacturer, with the tests performed here targeting one or 5 more of the envelope (env), nucleocapsid (n), spike (s), RNA-dependent RNA polymerase 6 (RdRp), and open reading frame-1 (ORF1) genes. The sensitivities of the tests to individual genes are comparable.<sup>9</sup> Although patients were enrolled and underwent assessment and sampling 7 8 at three hospitals in the region, RT-PCR was performed in a single regional virology laboratory 9 at the Royal Infirmary of Edinburgh.

10

11 An electronic form was embedded into the order of the combined nasal and throat swab to 12 prospectively record information on the indication for testing, symptom type, and duration of 13 symptoms. This form was completed by the usual care clinician at the time of testing. Data was 14 extracted from the electronic patient record (TrakCare; InterSystems Corporation, Cambridge, 15 MA, USA), laboratory information management system (iLaboratory, Advanced Expert Systems 16 Medical, Derby, United Kingdom), the Scottish Morbidity Record, the Scottish Drug Dispensing 17 Database, and the Scottish Care Information store. The Scottish Index of Multiple Deprivation 18 (SIMD), an area-based measure of deprivation, was used to define socioeconomic status of each 19 individual based on 31 indicators across 7 domains (income, employment, health, education, skills and training, housing, geographic access, and crime).<sup>10</sup> 20

21

22 Outcomes

Diagnostic performance of the index test was evaluated for a primary outcome of probable or confirmed COVID-19, and a secondary outcome of confirmed COVID-19 on serial testing. All clinical diagnoses were adjudicated by an independent, inter-disciplinary panel of clinicians using all information available within the electronic patient record, including contact history and review of all laboratory and radiological imaging performed.

6

7 The diagnosis of COVID-19 was based on the case definition proposed by the World Health Organisation.<sup>11</sup> The panel identified patients as suspected COVID-19 where they were admitted 8 9 to hospital with an acute respiratory illness (fever with at least one sign or symptom of 10 respiratory disease such as cough or shortness of breath) and had no alternative diagnosis that 11 fully explained the clinical presentation. The panel recorded clinical, laboratory and radiological 12 features of suspected COVID-19 without knowledge of the index and subsequent test results. 13 Patients with parameters consistent with COVID-19 were subsequently classified as probable 14 COVID-19 where all tests for the SARS-CoV-2 virus from any sample type were negative, or 15 confirmed COVID-19 where any test was positive during the hospital episode, or within 7 days 16 of the index presentation in those discharged.

17

For the evaluation of diagnostic performance for the primary outcome, patients were classified into the following groups: 1) *Confirmed COVID-19* in those with acute respiratory illness AND a positive test for SARS-CoV-2 (true positives); 2) *Probable COVID-19* in those with acute respiratory illness AND negative tests for SARS-CoV-2 AND no other diagnosis to explain the clinical presentation (false negatives); 3) Alternative diagnosis that fully explained their clinical presentation AND a positive test for SARS-CoV-2 (false positive); or 4) Alternative diagnosis

that fully explained their clinical presentation AND negative tests for SARS-CoV-2 (true
 negatives).

3

For evaluation of diagnostic performance for the secondary outcome, patients with confirmed
COVID-19 were classified as true positives, and those with probable COVID-19 were classified
as true negatives rather than false negatives.

- 7
- 8

#### 9 Sample size and power

Based on data from the Hubei and Shandong provinces and Beijing, China, we anticipated that approximately 32% (126/398) of combined nasal and throat swabs performed would be positive for SARS-CoV-2.<sup>6</sup> We recognise that there may be differences in the approach to the selection of patients for testing between countries, and therefore our sample size was based on a more conservative positive test rate of 20%. We estimated that with 1,000 patients, we will have 80% power to estimate the confidence interval for a sensitivity of 90% with lower and upper intervals of 85% and 95% respectively.

17

#### 18 **Statistical analysis**

Baseline characteristics, clinical features, and laboratory results are summarised as number (percentage) or median (interquartile range) for the study population, and stratified according to the adjudicated diagnosis. Two-by-two contingency tables were constructed to compare the index test (positive or negative) in those with and without the primary and secondary outcome on serial testing (reference standard). Test sensitivity, specificity, negative predictive value (NPV)

and positive predictive value (PPV) with 95% confidence intervals was determined in all participants and in pre-specified subgroups including age, sex, duration of symptoms prior to testing, fever, and respiratory tract symptoms. In patients where more than one test was performed, we report test results and compare diagnostic performance of the index test with the performance of multiple tests. All analyses were performed using R (version 3.6.1).

6

#### 7 Role of the funding source

8 The funders played no role in the study design, in the collection, analysis, and interpretation of 9 the data, in the writing of the report, or in the decision to submit the paper for publication. The 10 authors had full access to all the data in the study and had final responsibility for the decision to 11 submit for publication.

# 1 **Results**

2 Between April 3 and 20, 2020, we enrolled 1,369 consecutive patients (median age 68 3 [interquartile range, IQR 53-80] years, 47% women) who underwent a total of 3,822 combined 4 nasal and throat swab tests (median 2 [IQR 1-3] tests per patient) for symptoms of suspected 5 COVID-19 (Figure 1). The primary outcome occurred in 36% (496/1,369), of whom 65% 6 (323/496) and 35% (173/496) had confirmed and probable COVID-19, respectively. Of those 7 with an alternative diagnosis (64% [873/1,269]), the most frequent diagnoses were other 8 respiratory infections (25%, [221/873]) and non-communicable cardiorespiratory conditions 9 (21%, [181/873]), such as heart failure, chronic obstructive pulmonary disease and asthma.

10

Patients with confirmed or probable COVID-19 were older than those with an alternative diagnosis (median age of 71 [57-82] *versus* 67 [53-80] years), more likely to be men (57% [281/496] *versus* 52% [450/873]) and were less likely to be from an area of deprivation (13% [65/496] *versus* 20% [174/873]). However, they had similar comorbidities and were as likely to be receiving angiotensin converting enzyme inhibitors, corticosteroids or immunosuppressants at presentation (*Table 1 and eTable 1 in the Supplement*).

17

Compared to patients with an alternative diagnosis, those with confirmed or probable COVID-19 had a lower lymphocyte and neutrophil count (median  $1.14 \times 10^9$ /L *versus*  $1.44 \times 10^9$ /L and  $5.8 \times 10^9$ /L *versus*  $6.4 \times 10^9$ /L, respectively), but a higher C-reactive protein concentration (52 mg/dL *versus* 22 mg/dL) at presentation (*eTable 2 and 3 in the Supplement*). In patients with probable or confirmed COVID-19, compared to those with an alternative diagnosis, some symptoms and signs were more common, including fever on presentation (65% [322/496] *versus* 42%

1 [369/873]), upper and lower respiratory tract symptoms (13% [63/496] versus 10% [78/873]; 2 85% [419/496] versus 54% [473/873], respectively), and systemic symptoms (52% [257/496] 3 versus 28% [244/873]). In contrast, there were no differences in the frequency of neurological 4 (24% [118/496] versus 22% [191/873]) or gastrointestinal symptoms (22% [107/496] versus 5 24% [209/873]) (Figure 2a and eTable 4 in the Supplement). Patients with probable or 6 confirmed COVID-19 were six-times more likely to have radiological signs of infection on chest 7 imaging than those with an alternative diagnosis (64% [316/496] versus 11% [93/873]). Patients 8 with confirmed COVID-19 had similar symptoms as those with probable COVID-19 (Figure 2b 9 and eTable 5 in the Supplement), but were more likely to have lymphopenia, systemic 10 inflammation and radiological signs of infection.

11

12 The index test was positive in 255/496 (51%) patients with the primary outcome (*eTable 2 in the* 13 *Supplement*), giving a sensitivity, specificity, negative predictive value and positive predictive 14 value of 51.4% (95% confidence interval [CI] 48.8 to 54.1%), 99.5% (95% CI 99.0 to 99.8%), 15 78.3% (95% CI 76.0 to 80.4%) and 98.5% (95% CI 97.7 to 99.0%), respectively (*eTable 6 in the* 16 Supplement). Sensitivity was lower in patients from areas with the greatest deprivation (32.6% 17 [95% CI 21.6 to 43.9%] versus 53.9% [95% CI 45.7 to 62.1%], quintile with the most 18 deprivation compared to the quintile with the least deprivation). Otherwise, sensitivity remained 19 consistent across other patient demographic factors, comorbidities and symptoms (Figure 3a). 20 The negative predictive value of the index test was consistent across patient demographics and 21 comorbidities, but was lower in those with fever (70.3% [95% CI 66.3 to 74.2%]), lower 22 respiratory symptoms (69.5% [95% CI 66.1 to 73.0%]) and those with a longer duration of 23 symptoms prior to hospital admission (68.7% [95% CI 63.2 to 74.1%] versus 87.1% [95% CI

1 83.3 to 90.7%] for patients presenting ≥4 days after symptom onset compared to those presenting
2 within one day) (*Figure 3b*).

3

4 The majority of patients underwent serial testing (59.5%, 815/1,369) with 22.6% (310/1,369)5 undergoing 4 or more serial tests (eFigure 1 and 2, and eTable 6 in the Supplement). Of those 6 with confirmed COVID-19, patients with a negative index test result underwent more serial 7 testing than those with a positive index test result (95.6% [65/68] versus 65.9% [168/255] with 8 median test per patient of 4 [2-6] versus 2 [1-5] respectively). The median time between first and 9 second tests was shorter in patients with confirmed COVID-19 who had a negative index test 10 result and those with probable COVID-19 (1.7 [0.8-10.9] days and 1.2 [0.9-4.6] days 11 respectively) compared to patients with confirmed COVID-19 who had a positive index test result and those with an alternative diagnosis (6.8 [4.0-8.6] days and 6.1 [1.1-21.8] days 12 13 respectively). Sensitivity for the primary outcome increased in those undergoing 2, 3 or 4 serial 14 tests to 60.1% (95% CI 56.7 to 63.4%), 68.3% (95% CI 64.0 to 72.3%) and 77.6% (95% CI 72.7 15 to 81.9%), respectively (Figure 4 and eTable 7 in the Supplement). The negative predictive 16 value increased more modestly on serial testing; from 78.3% (76.0 to 80.4%) for the index test to 17 79.8% (75.0 to 83.9%) in those undergoing 4 serial tests. These observations persisted in a 18 sensitivity analysis restricted to patients who underwent at least 4 tests and for the secondary 19 outcome (Figure 4, eFigure 3 and 4, and eTable 8 in the Supplement).

20

Sensitivity of the index test for the secondary outcome of a diagnosis of confirmed COVID-19
on serial testing was 78.9% (95% CI 74.4 to 83.2%) (*eFigure 5a in the Supplement*). There was
no significant heterogeneity in sensitivity across patient demographics, comorbidities or

12

1	presenting symptoms. The negative predictive value of the index test was 93.8% (95% CI 92.4 to
2	95.2%) for a diagnosis of confirmed COVID-19 on serial testing (eFigure 5b in the
3	Supplement). The negative predictive value remained consistent across patient demographics
4	and comorbidities, but was lower in patients who presented with a fever (89.6% [95% CI 86.9 to
5	92.1%]) and those who had lower respiratory symptoms (91.5% [95% CI 89.4 to 93.6%]).

# 1 Discussion

2 In this prospective, multi-centre, cohort study, we evaluated the diagnostic performance of the 3 combined nasal and throat swab with RT-PCR for SARS-CoV-2 in consecutive patients admitted 4 to hospital with symptoms of suspected COVID-19. We report a number of potentially important 5 findings. First, a single test had excellent specificity, but limited sensitivity for an adjudicated 6 diagnosis of probable or confirmed COVID-19. Second, the sensitivity of the index test was 7 higher for patients with confirmed COVID-19 on serial testing, but still missed 1 in 5 patients 8 with the diagnosis. Third, diagnostic performance was similar in most patient subgroups, but the 9 sensitivity was lower in those from more deprived areas, and the negative predictive value was 10 lower in those presenting later following the onset of symptoms, and in those with fever or lower 11 respiratory symptoms. Finally, we observed a significant improvement in diagnostic sensitivity 12 with repeated testing on up to four occasions.

13

14 Our study has several strengths. This was a prospective, multi-centre study that was adequately 15 powered to evaluate the diagnostic performance of the combined nasal and throat swab. Patients 16 were enrolled using an electronic form embedded within clinical care across all secondary and 17 tertiary hospitals in the region. This permitted us to include all consecutive patients who 18 underwent testing for symptoms that were considered to be suggestive of COVID-19 by their 19 usual care clinician minimizing selection bias and ensuring our findings are representative of all 20 hospitalised patients across the region. The diagnosis was adjudicated by a multidisciplinary 21 panel of clinicians from a range of specialities involved in the care of patients with COVID-19, 22 including infectious disease, emergency medicine, general medicine and geriatric medicine, and 23 therefore our findings are relevant to clinical practice across secondary and tertiary care settings.

1 To our knowledge this is the first evaluation of the diagnostic performance of the combined nasal 2 and throat swab for a clinical diagnosis of COVID-19. The evaluation of the combined nasal and 3 throat swab is particularly important since this is the most widely used diagnostic modality to 4 identify or exclude SARS-CoV-2 infection. Although the RT-PCR test for SARS-CoV-2 has excellent in vitro analytical performance under carefully controlled laboratory conditions,9 5 6 diagnostic performance in clinical practice can vary due to multiple other factors, such as the site and quality of sampling, stage of disease, and viral multiplication or clearance.<sup>3,6,12</sup> Previous 7 8 studies have reported diagnostic sensitivities ranging from 50% to 100% for the combined nasal 9 and throat swab with a meta-analysis reporting a pooled meta-estimate of 89% (95% CI 81 to 94%).<sup>4,6,13-16</sup> However, these studies have been performed in relatively small, selected patient 10 11 cohorts, which limit the generalisability of study findings across the breadth of patients 12 presenting to hospitals with suspected COVID-19. Furthermore, the reference standard used in 13 these studies was either radiological findings on chest computed tomography, or the results of 14 subsequent RT-PCR tests, which inevitably leads to an increase in the estimated diagnostic 15 sensitivity. Indeed, when our reference standard was restricted to confirmed COVID-19 on serial 16 testing, diagnostic sensitivity increased from 51.4% to 78.9%.

17

In subgroup analyses, the diagnostic performance was similar in older patients, those with diabetes, known respiratory or cardiovascular disease. These findings are reassuring since these patient subgroups have been identified as those at the highest risk of death from COVID-19.<sup>17-19</sup> However, we observed that diagnostic sensitivity was lower in patients from the most deprived areas. This may reflect differences in the clinicians approach to testing by deprivation, rather than a consequence of deprivation itself, but this requires further evaluation. Furthermore, we

observed that negative predictive value was lower in those who presented late in the course of their illness, and those with symptoms of fever and lower respiratory tract symptoms. This is consistent with virological assessments of patients hospitalised with COVID-19 which showed that viral RNA shedding from the upper respiratory tract is typically highest at the onset of symptoms, but subsequently declines as the disease progresses.<sup>12,20</sup> The lower negative predictive value in those with typical clinical symptoms is likely to reflect a higher pre-test probability for COVID-19 in these patients.

8

9 Our findings have potentially important implications for the use and interpretation of this test in 10 clinical practice. Whilst the diagnosis of COVID-19 is still largely reliant on RT-PCR on 11 material collected on nose and throat swabs, clinicians need to be aware of the strengths and 12 limitations of testing when making decisions on the placement of patients within hospital settings 13 and discharge planning. In our study, the most conservative estimate of diagnostic sensitivity 14 was 51%, where the index test was negative in 1 in 2 patients with the primary outcome of 15 probable or confirmed COVID-19. Our most optimistic estimate of diagnostic sensitivity was 16 79%, where the index test was negative in 1 in 5 patients with the secondary outcome of 17 confirmed COVID-19. Whilst, the former may underestimate performance, the latter is certainly 18 an overestimate due to circular reasoning, whereby the test under evaluation is an essential 19 component of the reference standard.

20

In this consecutive series of hospitalised patients where testing was performed for symptoms at the discretion of the usual care clinician, our multi-disciplinary panel diagnosed probable COVID-19 in 12.6% of patients. The panel included representation from a broad range of

16

1 medical specialities involved in the assessment of these patients, and therefore their judgment is 2 likely to be representative of clinical practice. Our approach aims to provide insights into the 3 performance of the test as it is applied in clinical practice. Interestingly patients with probable 4 COVID-19 or confirmed COVID-19 and a negative index test were more likely to be retested 5 within the next 24-48 hours. This likely reflects the usual care clinician's uncertainty when 6 interpreting a negative test. Indeed for both the primary and secondary outcome, diagnostic 7 performance improved significantly with up to four serial tests, and this observation could 8 inform our approach to serial testing in practice with implications for patient flow and 9 management of hospitalised patients. Our findings also have implications when defining the reference standard for studies evaluating the performance of point of care<sup>21</sup> and laboratory 10 antibody tests<sup>22</sup> to determine those with and without prior infection. Future research should 11 12 evaluate performance in patients undergoing testing in the community, and determine whether 13 performance can be improved by incorporating a measure of sampling efficacy using epithelial cell counts<sup>23</sup>, or whether the diagnostic yield is higher in other sample types, such as saliva or 14 15 sputum.

16

We acknowledge our study has several limitations. We did not mandate the number of serial tests as all diagnostic testing was performed at the discretion of the treating clinician. Therefore those with a negative index test undergoing serial testing are likely to have had a higher pre-test probability than those undergoing a single test. Nevertheless, it is reassuring that a similar increase in diagnostic performance with serial testing was observed in a sensitivity analysis restricted to those patients who had a complete series of at least four tests. Further studies with systematic sampling in consecutive patients are required to validate this observation. In the

absence of an independent gold standard test for the diagnosis of COVID-19, our diagnostic 1 2 evaluation was based on clinical review of all tests ordered by the usual care clinician. As a 3 comprehensive panel of respiratory pathogens was not requested in all patients, it is likely we 4 have misclassified some patients as COVID-19 who had other viral or bacterial infections. We 5 may have overestimated the diagnosis of COVID-19 given the study was performed during the 6 peak of a pandemic. However, we reviewed all available clinical investigations including all 7 laboratory and imaging findings, and only defined patients with suspected COVID-19 where 8 there was no alternative diagnosis. Furthermore, the clinical features of those with probable or 9 confirmed COVID-19 were identical, suggesting no systematic bias was introduced during the 10 adjudication.

11

In conclusion, a single combined nasal and throat swab with RT-PCR for SARS-CoV-2 has
excellent specificity, but limited diagnostic sensitivity for the clinical diagnosis of COVID-19.
Diagnostic performance is significantly improved by repeated testing.

15

## 1 DataLoch COVID-19 Collaborators

- 2 Clinical Lead: Atul Anand
- 3 **Programme Lead:** Kathy Harrison
- 4 DataLoch Technical and Management Group: Catherine Stables, Ally Hume, David Homan,

5 Catriona Waugh, Jilly McKay, Chris Duncan, Ronnie Harkess

6 DataLoch Leadership Group: Kathy Harrison, Michael Gray, Colan Mahaffey, Pamela

7 Linksted, Atul Anand, Anoop SV Shah, Rob Baxter, Peter Cairns, Nicola Rigglesford, Martin

8 Egan, Nicholas L Mills

9 Infectious Diseases Unit: Daniella A Ross, Claire L Mackintosh, Oliver Koch, Kate Templeton,

10 Meghan R Perry

11 COVID-19 Clinical Data Review: Daniella A Ross, Anda Bularga, Hannah MM Preston,

12 Thomas J McCormick, Arjuna A Sivakumaran, Kathryn AW Knight, Rosie Callender, Anna K

13 Jamieson, Jonathan Wubetu, John P Kelly, Zaina Sharif, Ha Bao Trung Le, Jason Yang, Arun

- 14 Parajuli, Ed Whittaker, Oscar CN Maltby, Sarah H Goodwin, Louisa R Cary, Emma K Watson,
- 15 Thomas H Clouston, Julia Guerrero Enriquez, XinYi Ng

16 COVID-19 Adjudication Panel: Kuan Ken Lee, Daniella A Ross, Anda Bularga, Andrew R
17 Chapman, Yvonne K McFarlane, Kate H Regan, Richard P Biggers, John P Kelly, Kathryn AW
18 Knight, Hannah MM Preston, Thomas J McCormick, Anoop SV Shah, Atul Anand, Meghan R
19 Perry, Nicholas L Mills

NHS Lothian eHealth and Lothian Analytical Services: Alistair Stewart, Alastair Thomson,
Chris Duncan, Daniella Ene, Hazel Neilson, Juergen Caris, Maria McMenemy, Nazir Lone,
Nicola Rigglesford, Paul Schofield, Sophie McCall, Stephen Young, Tracey McKinley, Tracey
Rapson

## 1 Acknowledgements

2 This study was funded by a British Heart Foundation (BHF) Research Excellence Award (RE/18/6134217). DataLoch<sup>TM</sup> is funded by the University of Edinburgh, and the UK and 3 4 Scottish Governments as part of the Data Driven Innovation in Health & Social Care 5 programme. AA is supported by a Clinical Lectureship from the Chief Scientist Office 6 (PCL/18/05). KL and NLM are supported by a Clinical Research Training Fellowship 7 (FS/18/25/33454) and the Butler Senior Clinical Research Fellowship (FS/16/14/32023) from the 8 British Heart Foundation, respectively. DD is supported by the Medical Research Council 9 (MR/N013166/1). ARC is supported by a Starter Grant for Clinical Lecturers from the Academy 10 of Medical Sciences (SGL021\1075).

11

## 12 **Declaration of Interests**

13 All authors have no interests to declare.

14

## 15 Author Contributions

KKL, AA, ASVS and NLM conceived the study and its design. KKL, DR, AB, ARC, ASVS,
AA, MP, and NLM acquired the data. KKL and DD performed the analysis. KKL, DD, DR, AB,
CM, OK, IJ, SJ, ARC, ASVS, AA, MP, and NLM interpreted the data. KKL and NLM drafted
the manuscript. All authors revised the manuscript critically for important intellectual content
and provided their final approval of the version to be published. All authors are accountable for
the work.

# 1 References

2	1.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel					
3		coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.					
4	2.	Gates B. Responding to Covid-19 - A Once-in-a-Century Pandemic? N Engl J Med.					
5		2020;382(18):1677-1679.					
6	3.	Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.					
7		JAMA. 2020.					
8	4.	Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to					
9		RT-PCR. Radiology. 2020:200432.					
10	5.	Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in					
11		China. N Engl J Med. 2020;382(18):1708-1720.					
12	6.	Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical					
13		Specimens. JAMA. 2020.					
14	7.	Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2					
15		infection. The Lancet Infectious diseases. 2020;20(4):410-411.					
16	8.	Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19.					
17		JAMA. 2020.					
18	9.	Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-					
19		nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3).					
20	10.	The Scottish Index of Multiple Deprivation. Scottish Government.					
21		(https://www2.gov.scot/Topics/Statistics/SIMD) [Accessed July 8th 2020].					

1	11.	Global Surveillance for human infection with coronavirus disease (COVID-19).
2		(https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-
3		novel-coronavirus-(2019-ncov) [accessed May 10th 2020].
4	12.	Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
5		patients with COVID-2019. Nature. 2020;581(7809):465-469.
6	13.	Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase-
7		Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. Radiology.
8		2020:201343.
9	14.	Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
10		Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,
11		China. JAMA Intern Med. 2020.
12	15.	Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for
13		hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020;92(7):903-
14		908.
15	16.	Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus
16		Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020:200642.
17	17.	Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital
18		with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective
19		observational cohort study. BMJ. 2020;369.
20	18.	Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19
21		pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J.
22		2020;55(5).

1	19.	Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with
2		COVID-19 death in 17 million patients. Nature. 2020.
3	20.	Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected
4		with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective
5		cohort study. BMJ. 2020;369.
6	21.	Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG
7		combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020.
8	22.	Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
9		COVID-19. Nat Med. 2020;26(6):845-848.
10	23.	Bonnin P, Miszczak F, Kin N, et al. Study and interest of cellular load in respiratory
11		samples for the optimization of molecular virological diagnosis in clinical practice. BMC
12		Infect Dis. 2016;16:384.

13

	All	COVID-19*	Alternative diagnosis
	(n = 1,369)	(n = 496)	(n = 873)
Age, years	68 (53, 80)	71 (57, 82)	67 (51, 78)
Sex			
Men	731 (53%)	281 (57%)	450 (52%)
Women	638 (47%)	215 (43%)	423 (48%)
Ethnicity			
White	1088 (97%)	372 (97%)	716 (98%)
Other	29 (2.6%)	11 (2.9%)	18 (2.5%)
Deprivation			
1 (most deprivation)	239 (18%)	65 (13%)	174 (20%)
2	322 (24%)	116 (24%)	206 (24%)
3	236 (17%)	79 (16%)	157 (18%)
4	243 (18%)	93 (19%)	150 (17%)
5 (least deprivation)	319 (23%)	139 (28%)	180 (21%)
Duration of symptoms	3.0 (1.0, 5.0)	3.0 (2.0, 7.0)	2.0 (1.0, 4.0)
Comorbidities			
Diabetes mellitus	251 (18%)	96 (19%)	155 (18%)
Ischemic heart disease	137 (10%)	45 (9.1%)	92 (11%)
Heart failure	113 (8.3%)	38 (7.7%)	75 (8.6%)
Stroke	82 (6.0%)	27 (5.4%)	55 (6.3%)
COPD	206 (15%)	58 (12%)	148 (17%)
Asthma	113 (8.3%)	30 (6.0%)	83 (9.5%)
Liver cirrhosis	27 (2.0%)	8 (1.6%)	19 (2.2%)
End stage kidney disease	25 (1.8%)	12 (2.4%)	13 (1.5%)
Medications at presentation			
ACE inhibitors or ARBs	336 (25%)	129 (26%)	207 (24%)
Corticosteroids	223 (16%)	73 (15%)	150 (17%)
Immunosuppressants	34 (2.5%)	15 (3.0%)	19 (2.2%)

Table 1. Baseline characteristics of patients undergoing testing with suspected COVID-19 1

Values are No. (%) or median [inter-quartile range].

Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin receptor blockers; COPD = chronic obstructive pulmonary disease

\* Confirmed or probable COVID-19 with no alternative diagnosis

# Figure Legends

3	Figure 1. Flow diagram of study population.
4	
5	Figure 2. Radar plot of the clinical features of patients with (a) an adjudicated diagnosis of
6	confirmed or probable COVID-19 and those with an alternative diagnosis, and (b) confirmed
7	COVID-19 and those with probable COVID-19
8	
9	The following features used to adjudicate the diagnosis are illustrated: fever, systemic symptoms
10	(e.g. myalgia, fatigue, and arthralgia), upper respiratory tract symptoms, lower respiratory tract
11	symptoms, gastrointestinal symptoms, neurological symptoms, lymphopenia, systemic
12	inflammation, radiological features of infection.
13	
14	Figure 3. Forest plot of the (a) sensitivity and (b) negative predictive value of the index
15	combined nasal and throat swab for a diagnosis of confirmed or probable COVID-19 stratified
16	by subgroups
17	
18	Figure 4. Sensitivity of serial testing using the combined nasal and throat swab for the primary
19	(confirmed or probable COVID-19) and secondary (confirmed COVID-19) outcome.

#### Figure 1.









**(b)** 

## 1 **Figure 3.**

2

### 3 (a)

4

Subgroups	True positive	False negative		Sensitivity (95%Cl)
Demographics Age ≥68 years <68 years	155 100	120 121	<u>⊢</u> ∎	56.3 (50.5-62.2) 45.3 (38.8-51.8)
Sex Men Women	152 103	129 112	↓ <b>↓ ■</b> ■ 1	54.1 (48.3-59.9) 47.9 (41.3-54.6)
Deprivation (SIMD quintile) 1 (most deprived) 2 3 4 5 (least deprived)	21 65 43 48 75	44 51 36 45 64	←	32.6 (21.6-43.9) 56.0 (47.0-64.9) 54.4 (43.5-65.2) 51.6 (41.6-61.6) 53.9 (45.7-62.1)
<b>Comorbidities</b> Diabetes Yes No	52 203	44 197	⊢ <b>_</b> 1	54.1 (44.3-63.9) 50.7 (45.9-55.6)
Chronic respiratory disease Yes No	68 187	72 169	┝──╋──┤	48.6 (40.4-56.8) 52.5 (47.3-57.7)
Cardiovascular disease Yes No	45 210	44 197	┝──────┤	50.6 (40.3-60.8) 51.6 (46.8-56.4)
ACE inhibitor or ARBs Yes No	71 184	58 183	⊢_∎I	55.0 (46.5-63.5) 50.1 (45.0-55.2)
Corticosteroids or immunosuppresants Yes No	42 213	39 202	┝───₽──┤	51.8 (41.1-62.5) 51.3 (46.5-56.1)
Presenting symptoms Symptom duration ≤1 days 2-3 days ≥4 days	49 60 88	40 51 86		55.0 (44.8-65.2) 54.0 (44.8-63.2) 50.6 (43.2-57.9)
Fever Yes No	167 88	155 85	┝┷┻┷┥	51.9 (46.4-57.3) 50.9 (43.5-58.3)
Upper respiratory symptoms Yes No	30 224	33 208	⊢ <b>₽</b> -	47.7 (35.6-59.8) 51.8 (47.1-56.5)
Lower respiratory symptoms Yes No	213 41	206 35	<u>⊢</u> ∎	50.8 (46.1-55.6) 53.9 (42.8-64.9)
Overall	255	241	30 40 50 60 70 80	<b>51.4 (47.0-55.8)</b>

#### **(b**)

	Subgroups	True negative	False negative		Negative predictive value (95%CI)
3	Demographics				
4	Age ≥68 years <68 years	420 449	120 121	┝━━━┥	77.7 (74.2-81.2) 78.7 (75.3-82.0)
5	Sex Men Women	450 419	129 112	┝╌═╌┤	77.7 (74.3-81.0) 78.9 (75.4-82.3)
6 7	Deprivation (SIMD quintile) 1 (most deprived) 2 3 4 5 (least deprived)	174 206 156 149 178	44 51 36 45 64		79.7 (74.3-84.9) 80.0 (75.1-84.8) 81.1 (75.5-86.5) 76.7 (70.7-82.5) 73.5 (67.9-78.9)
8	<b>Comorbidities</b> Diabetes Yes No	155 714	44 197	⊢ <b>∎</b> 1	77.8 (71.9-83.4) 78.3 (75.7-81.0)
9	Chronic respiratory disease Yes No	297 572	72 169		80.4 (76.3-84.4) 77.2 (74.1-80.2)
10	Cardiovascular disease Yes No	178 691	44 197		80.0 (74.8-85.2) 77.8 (75.0-80.5)
11	ACE inhibitor or ARBs Yes No	206 663	58 183		77.9 (72.9-82.8) 78.3 (75.5-81.1)
12	Corticosteroids or immunosuppresants Yes No	163 706	39 202		80.5 (75.1-85.9) 77.7 (75.0-80.4)
13 14	Presenting symptoms Symptom duration ≤1 days 2-3 days ≥4 days	272 244 189	40 51 86		87.1 (83.3-90.7) 82.6 (78.2-86.8) 68.7 (63.2-74.1)
15	Fever Yes No	367 502	155 85	⊢■→ ⊢■→	70.3 (66.3-74.2) 85.5 (82.6-88.3)
16	Upper respiratory symptoms Yes No	77 792	33 208	← <b>■</b>     <b>■</b> _	69.8 (61.3-78.2) 79.2 (76.6-81.7)
17	Lower respiratory symptoms Yes No	471 398	206 35		69.5 (66.1-73.0) 91.8 (89.2-94.3)
18	Overall	869	241	65 70 75 80 85 90 95	<b>78.3 (75.8-80.7)</b>

